New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target?

Breast cancer is the most common malignant disease in women in the Western world, with an annual incidence rate of approximately 110/100,000 in females in the EU. Despite tremendous improvements in therapy in the last decades, one in five breast cancer patients dies from their disease. Accordingly, a strong clinical need for additional therapeutic options in breast cancer does exist. This is especially true in triple-negative tumors without overexpression of hormone receptors and HER2/neu.

Click here to view full article.